Brentwood, TN – June 5, 2026 – CyndRx, LLC, a medical device company focused on advancing vascular closure technology, today announced U.S. Food and Drug Administration (FDA) approval of its AbsorbaSeal™ Vascular Closure Device. FDA approval authorizes the commercialization of AbsorbaSeal™ in the United States and represents a significant regulatory milestone for the company as it begins to offer access to the technology for U.S. clinical use.
“With nearly 20 years of daily hands‑on experience using vascular closure devices, I appreciate how AbsorbaSeal brings a modern, bioabsorbable option to femoral arterial access site closure. Its FDA approval marks an important step forward for clinicians and patients who rely on safe and efficient closure technologies.” -Douglas Gesner, Chief Medical Officer, CyndRx
CyndRx is advancing its U.S. commercialization efforts and engaging with stakeholders across electrophysiology, interventional cardiology, vascular surgery, and interventional radiology to support broader adoption of the technology for procedures requiring femoral arterial access. AbsorbaSeal™ is an FDA-approved, innovative vascular closure device designed for acute arterial access site closure following catheter-based procedures.
“As a clinical investigator in the SEAL TO HEAL trial, I saw AbsorbaSeal™ deliver on the priorities that matter most to interventionalists regarding vascular access closure: reliable hemostasis, early ambulation, and no permanent implant left behind. I believe AbsorbaSeal™ has the potential to set a new benchmark for femoral access closure, benefiting patients, operators, and health systems alike.” -Vishal Gupta, MD MPH, Interventional Cardiologist, Department Chair, Internal Medicine and Director, Cardiac Catheterization Laboratory, Beacon Kalamazoo Medical Center, Professor of Clinical Medicine, Western Michigan University Homer Stryker M.D. School of Medicine
AbsorbaSeal™ is designed to reduce procedural complexity and provide a patient-friendly solution that avoids the use of permanent and collagen-based implants.
Source: Company Press Release
June 5, 2026
For more information, visit https://cyndrx.com
CyndRx is a medical technology company based in Brentwood, Tennessee, dedicated to developing and commercializing innovative surgical instruments and vascular closure technologies. The company focuses on delivering clinically meaningful solutions that enhance procedural efficiency, support vessel healing, and improve patient care. Please refer to the AbsorbaSeal Instructions for Use for a complete listing of indications, contraindications, warnings, and precautions.
